Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.
Alexander DrilonGeoffrey R OxnardDaniel S W TanHerbert Ho-Fung LoongMelissa JohnsonJustin GainorCaroline E McCoachOliver GautschiBenjamin BesseByoung C ChoNir PeledJared WeissYu-Jung KimYuichiro OheMakoto NishioKeunchil ParkJyoti PatelTakashi SetoTomohiro SakamotoEzra RosenManisha H ShahFabrice BarlesiPhilippe A CassierLyudmila BazhenovaFilippo De BraudElena GarraldaVamsidhar VelchetiMiyako SatouchiKadoaki OhashiNathan A PennellKaren L ReckampGrace K DyJürgen WolfBenjamin SolomonGerald FalchookKevin EbataMichele NguyenBinoj NairEdward Y ZhuLuxi YangXin HuangElizabeth OlekS Michael RothenbergKoichi GotoVivek SubbiahPublished in: The New England journal of medicine (2020)
Selpercatinib had durable efficacy, including intracranial activity, with mainly low-grade toxic effects in patients with RET fusion-positive NSCLC who had previously received platinum-based chemotherapy and those who were previously untreated. (Funded by Loxo Oncology and others; LIBRETTO-001 ClinicalTrials.gov number, NCT03157128.).